Literature DB >> 19011377

Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway.

Jonathan R St-Germain1, Jihong Chen, Qiao Li.   

Abstract

Transcriptional coactivator CBP is involved in the regulation of an array of biological processes including cellular differentiation, proliferation and survival. The function of CBP is critical for proper embryonic development and is relevant in cancer biology. Although much is known about the functional roles of CBP in these cellular processes, fewer studies have assessed what in turn regulates CBP activity per se. It has been reported that CBP colocalizes with PML bodies which are nuclear structures disrupted in acute promyelocytic leukemia. However, the biological relevance of CBP localization to PML nuclear bodies is still unclear. In this study, we demonstrate that histone deacetylase inhibitors such as valproic acid, a therapeutically relevant compound used for the treatment of epilepsy, modulates CBP activity. Valproic acid reduces the steady-state level of CBP by inducing CBP degradation through the ubiquitin-proteasome pathway, while increasing the colocalization of CBP with ubiquitin nuclear speckles and with PML nuclear bodies. Our results suggest that PML nuclear bodies are nuclear sites involved in the ubiquitin-dependent degradation of CBP, providing novel insights in the regulation of CBP function and highlighting the relevance of its localization to PML nuclear bodies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19011377     DOI: 10.4161/epi.3.6.7203

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  24 in total

Review 1.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

2.  Interplay of bromodomain and histone acetylation in the regulation of p300-dependent genes.

Authors:  Jihong Chen; Feras M Ghazawi; Qiao Li
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

3.  PML regulates PER2 nuclear localization and circadian function.

Authors:  Takao Miki; Zhixiang Xu; Misty Chen-Goodspeed; Mingguang Liu; Anita Van Oort-Jansen; Michael A Rea; Zhaoyang Zhao; Cheng Chi Lee; Kun-Sang Chang
Journal:  EMBO J       Date:  2012-01-24       Impact factor: 11.598

Review 4.  Regulation of histone modifying enzymes by the ubiquitin-proteasome system.

Authors:  Chunbin Zou; Rama K Mallampalli
Journal:  Biochim Biophys Acta       Date:  2014-01-03

5.  Compromised mitochondrial complex II in models of Machado-Joseph disease.

Authors:  Mário N Laço; Catarina R Oliveira; Henry L Paulson; A Cristina Rego
Journal:  Biochim Biophys Acta       Date:  2011-10-20

6.  Valproic Acid Thermally Destabilizes and Inhibits SpyCas9 Activity.

Authors:  Xinlai Cheng
Journal:  Mol Ther       Date:  2020-08-25       Impact factor: 11.454

7.  Cellular senescence and protein degradation: breaking down cancer.

Authors:  Xavier Deschênes-Simard; Frédéric Lessard; Marie-France Gaumont-Leclerc; Nabeel Bardeesy; Gerardo Ferbeyre
Journal:  Cell Cycle       Date:  2014-05-27       Impact factor: 4.534

8.  Trafficking of the transcription factor Nrf2 to promyelocytic leukemia-nuclear bodies: implications for degradation of NRF2 in the nucleus.

Authors:  Melanie Theodore Malloy; Deneshia J McIntosh; Treniqka S Walters; Andrea Flores; J Shawn Goodwin; Ifeanyi J Arinze
Journal:  J Biol Chem       Date:  2013-03-29       Impact factor: 5.157

Review 9.  The Arc of cognition: Signaling cascades regulating Arc and implications for cognitive function and disease.

Authors:  Irina Epstein; Steven Finkbeiner
Journal:  Semin Cell Dev Biol       Date:  2018-05       Impact factor: 7.727

10.  Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes.

Authors:  Sarah J Cullen; Subramaniam Ponnappan; Usha Ponnappan
Journal:  Mol Immunol       Date:  2009-10-01       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.